Pathologic Complete Response After Neoadjuvant Chemoradiation in a Patient with Gastric Neuroendocrine Cancer.
| Autor: | Laughlin B; Radiation Oncology, University of Arizona Cancer Center, Tucson, USA., Scott A; Hematology and Oncology, University of Arizona Cancer Center, Tucson, USA., Goyal U; Radiation Oncology, University of Arizona Cancer Center, Tucson, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Cureus [Cureus] 2019 Jul 23; Vol. 11 (7), pp. e5214. Date of Electronic Publication: 2019 Jul 23. |
| DOI: | 10.7759/cureus.5214 |
| Abstrakt: | Neuroendocrine tumors are about 0.5% of all malignancies. Specifically, for gastrointestinal (GI) malignancies, neuroendocrine tumor incidence is approximately 1%-2% per year. Gastric neuroendocrine neoplasms are rare and consist of various tumor types with differing histomorphology, pathogenesis, and biological behavior. Following surgery, post-operative chemotherapy is generally considered the standard of care. Our case report demonstrates the potential benefit of neoadjuvant concurrent chemoradiotherapy prior to surgery for a malignant gastric neuroendocrine tumor. While radiotherapy has been demonstrated to possibly provide a survival benefit in the treatment of GI neuroendocrine tumors, its use in treatment, particularly neoadjuvantly, needs to be further assessed. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2019, Laughlin et al.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|